Profile data is unavailable for this security.
About the company
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
- Revenue in AUD (TTM)24.21m
- Net income in AUD-143.78m
- Incorporated2004
- Employees81.00
- LocationMesoblast LtdL 38 55 Collins StMELBOURNE 3000AustraliaAUS
- Phone+61 39639-6036
- Fax+61 39639-6030
- Websitehttps://www.mesoblast.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rubicon Research Ltd | 246.60m | 31.82m | 1.97bn | 1.14k | 59.18 | -- | 51.97 | 7.97 | 13.07 | 13.07 | 102.06 | -- | -- | -- | -- | 14,424,080.00 | -- | -- | -- | -- | 68.82 | -- | 12.90 | -- | -- | 12.92 | -- | -- | 50.40 | -- | 47.63 | -- | -- | -- |
| Suzhou Ribo Life Science Co Ltd | 36.91m | -45.23m | 1.97bn | 404.00 | -- | -- | -- | 53.33 | -1.56 | -1.56 | 1.27 | -0.4122 | -- | -- | -- | -- | -- | -- | -- | -- | 90.90 | -- | -131.95 | -- | 0.9173 | -14.93 | 0.8949 | -- | 324,052.30 | -- | 36.93 | -- | -- | -- |
| Pell Bio Med Technology Co Ltd | 1.34m | -16.73m | 2.00bn | -- | -- | 42.72 | -- | 1,490.69 | -6.31 | -6.31 | 0.5068 | 16.15 | 0.0185 | 6.36 | 5.95 | -- | -23.99 | -- | -31.28 | -- | -31.12 | -- | -1,297.25 | -- | 3.47 | -- | 0.1652 | -- | 8.86 | -- | 2.34 | -- | -- | -- |
| Nanjing Leads Biolabs Co Ltd | 0.00 | -58.85m | 2.12bn | 192.00 | -- | 93.71 | -- | -- | -2.02 | -2.02 | 0.00 | 0.6344 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.01 | -- | 0.7407 | -- | -100.00 | -- | 16.85 | -- | -- | -- |
| Onesource Specialty Pharma Ltd | 219.00m | 3.21m | 2.32bn | 1.41k | 720.15 | -- | 50.61 | 10.58 | 1.82 | 1.76 | 129.84 | -- | -- | -- | -- | 10,051,880.00 | -- | -- | -- | -- | 70.99 | -- | 1.46 | -- | -- | 0.8886 | -- | -- | 740.43 | -- | 95.27 | -- | -- | -- |
| HitGen Inc | 102.15m | 23.38m | 2.32bn | 483.00 | 100.05 | 7.70 | -- | 22.71 | 0.2824 | 0.2824 | 1.24 | 3.67 | 0.2726 | 6.37 | 4.69 | 1,032,114.00 | 6.18 | 3.06 | 6.87 | 3.36 | 55.23 | 53.55 | 22.67 | 14.48 | 5.12 | 6.59 | 0.1674 | 34.32 | 14.99 | 10.08 | 26.13 | -15.65 | 3.16 | -- |
| InventisBio Co Ltd | 36.99m | -23.83m | 2.48bn | 185.00 | -- | 7.26 | -- | 66.99 | -0.2012 | -0.2012 | 0.3122 | 2.88 | 0.0988 | -- | 1.03 | 975,824.70 | -6.36 | -32.89 | -6.76 | -35.22 | 99.41 | -- | -64.41 | -682.73 | -- | -- | 0.0127 | -- | -9.02 | 25.00 | 15.41 | -- | -3.97 | -- |
| Syngene International Ltd | 574.02m | 54.33m | 2.56bn | 6.53k | 47.25 | -- | 20.89 | 4.45 | 8.72 | 8.72 | 92.16 | -- | -- | -- | -- | 5,694,474.00 | -- | 8.14 | -- | 10.44 | 75.26 | 71.29 | 9.46 | 15.03 | -- | 5.73 | -- | -- | 4.41 | 12.60 | -2.71 | 3.78 | 3.67 | -- |
| Mesoblast Ltd | 91.92m | -132.67m | 2.67bn | 81.00 | -- | 3.30 | -- | 29.06 | -0.1035 | -0.1035 | 0.0717 | 0.627 | 0.0911 | 1.20 | 2.95 | 1,134,840.00 | -13.15 | -13.19 | -15.28 | -14.68 | 57.98 | -132.14 | -144.33 | -957.40 | 1.41 | -4.74 | 0.1904 | -- | 191.39 | -11.76 | -16.13 | -- | -20.16 | -- |
| Keymed Biosciences Inc | 178.72m | -52.73m | 2.69bn | 1.47k | -- | 4.11 | -- | 15.04 | -1.12 | -1.12 | 3.78 | 12.20 | 0.2068 | 0.3382 | 15.10 | 790,836.80 | -6.10 | -40.63 | -7.27 | -44.60 | 95.19 | -- | -29.48 | -593.20 | 3.74 | -- | 0.2145 | -- | 20.91 | -- | -43.38 | -- | 28.05 | -- |
| Mabwell Shanghai Bioscience Co Ltd | 127.97m | -194.15m | 2.74bn | 1.36k | -- | 17.60 | -- | 21.45 | -2.37 | -2.37 | 1.56 | 1.90 | 0.1384 | 0.3458 | 14.57 | 441,048.00 | -21.06 | -29.90 | -36.19 | -36.18 | 88.72 | 85.56 | -152.14 | -1,188.68 | 0.8093 | -10.82 | 0.7353 | -- | 56.28 | 46.68 | 0.9031 | -- | 12.25 | -- |
| Ascentage Pharma Group International | 80.04m | -237.53m | 3.02bn | 605.00 | -- | 20.68 | -- | 37.72 | -4.05 | -4.05 | 1.36 | 2.18 | 0.1270 | 3.70 | 0.9505 | 785,790.80 | -37.68 | -30.84 | -60.56 | -41.94 | 90.87 | 94.02 | -296.81 | -252.93 | 1.53 | -- | 0.7174 | -- | 341.77 | 132.25 | 56.20 | -- | -21.49 | -- |
| Telix Pharmaceuticals Ltd | 1.13bn | -10.02m | 3.31bn | 1.12k | -- | 5.66 | 163.54 | 2.93 | -0.0296 | -0.0296 | 3.34 | 1.72 | 0.7639 | 13.90 | 7.44 | 1,008,962.00 | -0.6772 | -4.82 | -0.8545 | -6.41 | 47.51 | 55.04 | -0.8864 | -5.75 | 1.27 | 3.64 | 0.5293 | -- | 55.61 | 195.18 | -121.15 | -- | 202.38 | -- |
Data as of Mar 03 2026. Currency figures normalised to Mesoblast Ltd's reporting currency: Australian Dollar AUD
15.65%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| State Street Global Advisors, Australia, Ltd.as of 08 Dec 2025 | 44.97m | 3.49% |
| M&G Investment Management Ltd.as of 31 Oct 2025 | 40.86m | 3.17% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 34.87m | 2.70% |
| Vanguard Investments Australia Ltd.as of 31 Jan 2026 | 19.14m | 1.48% |
| Thorney Investment Group Australia Pty Ltd.as of 30 Sep 2025 | 14.12m | 1.09% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 12.25m | 0.95% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 12.07m | 0.94% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 9.09m | 0.71% |
| BetaShares Capital Ltd.as of 30 Jan 2026 | 7.33m | 0.57% |
| DFA Australia Ltd.as of 31 Jan 2026 | 7.20m | 0.56% |
More ▼
Data from 31 Dec 2025 - 27 Feb 2026Source: FactSet Research Systems Inc.
